Trials / Completed
CompletedNCT00038714
A Trial Study of SGN-00101 in Treating Pediatric Patients With Recurrent Respiratory Papillomatosis
A Phase II Trial of SGN-00101 In The Treatment of Pediatric Recurrent Respiratory Papillomatosis
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 27 (estimated)
- Sponsor
- Nventa Biopharmaceuticals Corporation · Industry
- Sex
- All
- Age
- 2 Years – 18 Years
- Healthy volunteers
- Not accepted
Summary
Recurrent Respiratory Papillomatosis (RRP) causes wart-like lesions along the throat area and can obstruct the airway or become malignant. The cause has been related to specific types of Human Papillomavirus (HPV). The purpose of the study is to assess the clinical effectiveness of a trial drug, SGN-00101, in children with RRP and also assess its safety.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SGN-00101 |
Timeline
- Start date
- 2001-11-01
- Completion
- 2004-01-01
- First posted
- 2002-06-05
- Last updated
- 2007-06-27
Locations
8 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00038714. Inclusion in this directory is not an endorsement.